Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120472026> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3120472026 endingPage "S733" @default.
- W3120472026 startingPage "S732" @default.
- W3120472026 abstract "Abstract Background Ampicillin/sulbactam is a recommended first-line agent for the treatment of aspiration pneumonia. Due to the ampicillin/sulbactam shortage, beginning in March 2019, alternative therapies, such as ceftriaxone plus metronidazole, have been utilized more frequently. The objective of this study is to examine clinical outcomes in adult inpatients treated with either ampicillin/sulbactam or ceftriaxone/metronidazole for aspiration pneumonia. Methods An electronic health record report identified patients ≥18 years of age that received ampicillin/sulbactam (pre-March 2019) or ceftriaxone/metronidazole (post-March 2019) with the indication of aspiration pneumonia. The primary objective was to describe 30-day all-cause readmission rates for patients that received ampicillin/sulbactam compared to ceftriaxone/metronidazole. The secondary objectives included hospital length of stay (LOS), 30-day all-cause mortality, C.difficile infection (CDI) within 3 months, and total antibiotic costs. Results A total of 86 patients (50 received ampicillin/sulbactam and 36 received ceftriaxone/ metronidazole) were included. Demographics were similar between groups. There was no significant difference in 30-day all-cause readmission rates (30% vs 19%, p=0.322). The ampicillin/sulbactam group, however, was found to have a significantly higher rate of 30-day all-cause mortality (12% vs 0%, p=0.038). Additionally, total duration of therapy was found to be significantly shorter in the ampicillin/sulbactam group (5 vs 7 days, p=0.002) with reduced overall cost of therapy($130 vs $235, p< 0.001). No differences were observed in hospital LOS or CDI within 3 months. Conclusion No difference was observed in 30-day all-cause readmissions in patients receiving ampicillin/sulbactam compared to ceftriaxone/metronidazole for the treatment of aspiration pneumonia. Further analyses are recommended to evaluate the impact on 30-day all-cause mortality. Disclosures All Authors: No reported disclosures" @default.
- W3120472026 created "2021-01-18" @default.
- W3120472026 creator A5014328260 @default.
- W3120472026 creator A5060796245 @default.
- W3120472026 creator A5069066377 @default.
- W3120472026 date "2020-10-01" @default.
- W3120472026 modified "2023-09-27" @default.
- W3120472026 title "1461. Impact of the Ampicillin/Sulbactam Shortage on Antibiotic Prescribing and Clinical Outcomes for Adult Inpatients with Aspiration Pneumonia" @default.
- W3120472026 doi "https://doi.org/10.1093/ofid/ofaa439.1642" @default.
- W3120472026 hasPublicationYear "2020" @default.
- W3120472026 type Work @default.
- W3120472026 sameAs 3120472026 @default.
- W3120472026 citedByCount "0" @default.
- W3120472026 crossrefType "journal-article" @default.
- W3120472026 hasAuthorship W3120472026A5014328260 @default.
- W3120472026 hasAuthorship W3120472026A5060796245 @default.
- W3120472026 hasAuthorship W3120472026A5069066377 @default.
- W3120472026 hasBestOaLocation W31204720261 @default.
- W3120472026 hasConcept C126322002 @default.
- W3120472026 hasConcept C141071460 @default.
- W3120472026 hasConcept C2776021129 @default.
- W3120472026 hasConcept C2776102371 @default.
- W3120472026 hasConcept C2776520383 @default.
- W3120472026 hasConcept C2777396551 @default.
- W3120472026 hasConcept C2777914695 @default.
- W3120472026 hasConcept C2778478555 @default.
- W3120472026 hasConcept C2779631663 @default.
- W3120472026 hasConcept C2781338923 @default.
- W3120472026 hasConcept C501593827 @default.
- W3120472026 hasConcept C71924100 @default.
- W3120472026 hasConcept C86803240 @default.
- W3120472026 hasConcept C89423630 @default.
- W3120472026 hasConcept C94665300 @default.
- W3120472026 hasConceptScore W3120472026C126322002 @default.
- W3120472026 hasConceptScore W3120472026C141071460 @default.
- W3120472026 hasConceptScore W3120472026C2776021129 @default.
- W3120472026 hasConceptScore W3120472026C2776102371 @default.
- W3120472026 hasConceptScore W3120472026C2776520383 @default.
- W3120472026 hasConceptScore W3120472026C2777396551 @default.
- W3120472026 hasConceptScore W3120472026C2777914695 @default.
- W3120472026 hasConceptScore W3120472026C2778478555 @default.
- W3120472026 hasConceptScore W3120472026C2779631663 @default.
- W3120472026 hasConceptScore W3120472026C2781338923 @default.
- W3120472026 hasConceptScore W3120472026C501593827 @default.
- W3120472026 hasConceptScore W3120472026C71924100 @default.
- W3120472026 hasConceptScore W3120472026C86803240 @default.
- W3120472026 hasConceptScore W3120472026C89423630 @default.
- W3120472026 hasConceptScore W3120472026C94665300 @default.
- W3120472026 hasIssue "Supplement_1" @default.
- W3120472026 hasLocation W31204720261 @default.
- W3120472026 hasLocation W31204720262 @default.
- W3120472026 hasLocation W31204720263 @default.
- W3120472026 hasOpenAccess W3120472026 @default.
- W3120472026 hasPrimaryLocation W31204720261 @default.
- W3120472026 hasRelatedWork W2122131929 @default.
- W3120472026 hasRelatedWork W2167614675 @default.
- W3120472026 hasRelatedWork W2560399134 @default.
- W3120472026 hasRelatedWork W2978292717 @default.
- W3120472026 hasRelatedWork W2984212013 @default.
- W3120472026 hasRelatedWork W3120472026 @default.
- W3120472026 hasRelatedWork W3157430073 @default.
- W3120472026 hasRelatedWork W3171180029 @default.
- W3120472026 hasRelatedWork W4296620523 @default.
- W3120472026 hasRelatedWork W2995318613 @default.
- W3120472026 hasVolume "7" @default.
- W3120472026 isParatext "false" @default.
- W3120472026 isRetracted "false" @default.
- W3120472026 magId "3120472026" @default.
- W3120472026 workType "article" @default.